Manufacturers: Encoded Therapeutics
ETX301 (ETX-301) is an investigational AAV9-based vectorized microRNA gene therapy being developed by Encoded Therapeutics for post-amputation neuroma pain, with a planned Investigational New Drug (IND) submission in 2027.
ETX301 (ETX-301) is an investigational AAV9-based vectorized microRNA gene therapy being developed by Encoded Therapeutics for post-amputation neuroma pain, with a planned Investigational New Drug (IND) submission in 2027.
AAV9-delivered vectorized microRNA designed to selectively and durably knock down SCN9A, which encodes the sodium channel NaV1.7, thereby reducing pain signaling in post-amputation neuroma pain.
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
